Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 113

1.

Prevalence of "unclassified" HPV genotypes among women with abnormal cytology.

Annunziata C, Stellato G, Greggi S, Sanna V, Curcio MP, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2018 Jul 24;13:26. doi: 10.1186/s13027-018-0199-0. eCollection 2018.

2.

The role of sensing peptides in the cross-talk between microbiota and human cancer cells.

Tornesello AL, Buonaguro L, Tornesello ML, Buonaguro FM.

Mini Rev Med Chem. 2018 Jul 12. doi: 10.2174/1389557518666180713112119. [Epub ahead of print]

PMID:
30003859
3.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

4.

Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers.

Tornesello ML, Annunziata C, Tornesello AL, Buonaguro L, Buonaguro FM.

Cancers (Basel). 2018 Jun 22;10(7). pii: E213. doi: 10.3390/cancers10070213. Review.

5.

Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.

Annunziata C, Pezzuto F, Greggi S, Ionna F, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Int J Cancer. 2018 Sep 1;143(5):1153-1161. doi: 10.1002/ijc.31412. Epub 2018 Apr 17.

PMID:
29603728
6.

The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma.

Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML.

Int J Mol Sci. 2018 Mar 28;19(4). pii: E1007. doi: 10.3390/ijms19041007. Review.

7.

Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia.

Starita N, Buonaguro L, Buonaguro FM, Tornesello ML.

J Transl Med. 2018 Mar 21;16(1):77. doi: 10.1186/s12967-018-1456-0.

8.

Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.

Petrizzo A, Mauriello A, Luciano A, Rea D, Barbieri A, Arra C, Maiolino P, Tornesello M, Gigantino V, Botti G, Ciliberto G, Buonaguro FM, Tagliamonte M, Buonaguro L.

Oncotarget. 2017 Dec 8;9(3):3576-3589. doi: 10.18632/oncotarget.23181. eCollection 2018 Jan 9.

9.

Corrigendum to "New vaccination strategies in liver cancer" [Cytokine Growth Factor Rev. 36 (2017) 125-129].

Buonaguro L; HEPAVAC Consortium.

Cytokine Growth Factor Rev. 2017 Sep 12. pii: S1359-6101(17)30149-1. doi: 10.1016/j.cytogfr.2017.09.001. [Epub ahead of print] No abstract available.

PMID:
28918939
10.

New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology.

Tornesello AL, Buonaguro L, Tornesello ML, Buonaguro FM.

Molecules. 2017 Aug 2;22(8). pii: E1282. doi: 10.3390/molecules22081282. Review.

11.

New vaccination strategies in liver cancer.

Buonaguro L; HEPAVAC Consortium.

Cytokine Growth Factor Rev. 2017 Aug;36:125-129. doi: 10.1016/j.cytogfr.2017.06.010. Epub 2017 Jun 23. No abstract available. Erratum in: Cytokine Growth Factor Rev. 2017 Sep 12;:.

PMID:
28688773
12.

Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma.

Starita N, Di Monta G, Cerasuolo A, Marone U, Anniciello AM, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2017 Jun 19;12:35. doi: 10.1186/s13027-017-0147-4. eCollection 2017.

13.

Use of adjuvants for immunotherapy.

Circelli L, Tornesello M, Buonaguro FM, Buonaguro L.

Hum Vaccin Immunother. 2017 Aug 3;13(8):1774-1777. doi: 10.1080/21645515.2017.1321725. Epub 2017 Jun 12.

14.

Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma.

Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2017 May 19;12:27. doi: 10.1186/s13027-017-0138-5. eCollection 2017. Review.

15.

Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma.

Cerasuolo A, Annunziata C, Tortora M, Starita N, Stellato G, Greggi S, Maglione MG, Ionna F, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Oncotarget. 2017 May 23;8(21):34070-34081. doi: 10.18632/oncotarget.15977.

16.

Application of the Immunoscore as prognostic tool for hepatocellular carcinoma.

Petrizzo A, Buonaguro L.

J Immunother Cancer. 2016 Nov 15;4:71. eCollection 2016.

17.

Immunological effects of a novel RNA-based adjuvant in liver cancer patients.

Circelli L, Petrizzo A, Tagliamonte M, Heidenreich R, Tornesello ML, Buonaguro FM, Buonaguro L.

Cancer Immunol Immunother. 2017 Jan;66(1):103-112. doi: 10.1007/s00262-016-1923-5. Epub 2016 Nov 10.

PMID:
27832318
18.

Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery.

Petrizzo A, Caruso FP, Tagliamonte M, Tornesello ML, Ceccarelli M, Costa V, Aprile M, Esposito R, Ciliberto G, Buonaguro FM, Buonaguro L.

Sci Rep. 2016 Jul 8;6:29258. doi: 10.1038/srep29258.

19.

Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?

Gargiulo P, Della Pepa C, Berardi S, Califano D, Scala S, Buonaguro L, Ciliberto G, Brauchli P, Pignata S.

Cancer Treat Rev. 2016 Jul;48:61-8. doi: 10.1016/j.ctrv.2016.06.008. Epub 2016 Jun 18. Review.

PMID:
27362548
20.

Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.

Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, Botti G, Buonaguro FM, Tornesello ML.

Oncotarget. 2016 Aug 23;7(34):54253-54262. doi: 10.18632/oncotarget.9801.

Supplemental Content

Loading ...
Support Center